Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
Published . Updated .
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Directly affected
- MRK Merck
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Source: BioPharma Dive
The price since 14 Sep 2026: Acadia Healthcare (ACHC) versus the S&P 500
Since the first closing price after “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” Acadia Healthcare (ACHC) is +10.34%. The S&P 500 fund (SPY) is +1.21% over the same days, a +9.13% difference versus the market.
Filings that name Acadia Healthcare (ACHC) around 14 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 15 days after publication, inside 30 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 3 days before publication, inside 30 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 42 days before publication, inside 60 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
- Donald J Trump sell GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies mentioned with this story
- ACHC Acadia Healthcare
For “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
The 14 Sep 2026 story “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results” names Acadia Healthcare (ACHC) because of this story.
For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.